Epigenetics in Metabolic and Neurological Disorders 2.0
A special issue of Epigenomes (ISSN 2075-4655).
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 10521
Special Issue Editor
Interests: medical genetics; genetics and epigenetics of human reproduction; stem cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epigenetics is a gene regulation mechanism based on chemical modifications of genomic DNA and histone proteins, as well as the production of miRNA. Epigenetic alterations can cause congenital disorders, including genomic imprinting disorders, X-chromosome inactivation disorders, and epigenetic regulation-associated molecule disorders. However, it has recently been suggested that epigenetic mechanisms could also be related to an increased susceptibility to metabolic and neurological disorders throughout lifetime.
Epigenetic modifications in DNA are vulnerable to environmental stress, such as malnutrition, environmental chemicals, and mental stress, mostly occurring during the early period of life, but also during prenatal life and even during maternal and paternal gametogenesis.
Since the epigenome has a reversible property, induced epigenomic alterations can be potentially restored, leading to the possibility of an epigenomic-based preemptive medicine consisting of early detection of epigenomic signatures and early intervention.
In this Special Issue, I would like to invite review and original articles that focus on the epigenetic basis of the susceptibility of metabolic and neurological diseases in the frame of preventive strategies involving early life, prenatal life, and periconceptional life.
The conjunct Special Issue in IJMS: Epigenetics in Metabolic and Neurological Disorders 2.0
Prof. Dr. Liborio Stuppia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.